HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $30
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $65 to $30.
ALX Oncology Announced First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV® (enfor
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session.
AMC Preferred Equity Units, Accolade And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Friday. Here are some big stocks recording gains in today’s session.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…
ALX Oncology Holdings Q2 EPS $(0.81) Down From $(0.35) YoY
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.81) per share. This is a 131.43 percent decrease over losses of $(0.35) per share from the same period last year.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion.